NCT06225830 Unlocking Movement Potential: Enhancing Parkinson's Disease Treatment With Robotic EksoSkeleton
| NCT ID | NCT06225830 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Albert Einstein Healthcare Network |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2024-06-04 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2024-06-04 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to see how well therapy with the Eksobionic Exoskeleton (Esko) works for people with Parkinson's disease (PWPD). Esko is a robotic device that provides high repetition and intensity training. The investigators will examine its impact on walking, balance, and quality of life before, during and after an eight-week intervention program. The results will lay the groundwork for future trials, potentially leading to long-term improvements in mobility and quality of life for PWPD.
Eligibility Criteria
Inclusion Criteria: 1. Physician diagnosed idiopathic Parkinson's disease 2. All Hoehn and Yahr (H\&Y) stages will be eligible for inclusion in the study 3. Able to consent to participation in the research study 4. Pt agreeable to participate in 45-60 minutes of high intensity (RPE 14-17 for 30 minutes) gait training/ physical therapy. 5. Sufficient upper extremity strength to use a front wheeled walker 6. Pt to have self- reported walking/balance deficits 7. Age: Over age 18 8. Must be able to tolerate at least 15 min upright 9. Weigh 220 pounds (100kg) or less 10. Approximately between 5'0" and 6'4" tall 11. Have near normal range of motion in hips, knees, and ankles "Can you stand up and straighten your knees even for just a second?" or "Can you lay flat and straighten your knees so there is no bend in the knee?" Exclusion Criteria: 1. Currently involved in another intervention study or physical therapy course of care 2. Concurrent neurological disease 3. Leg length discrepancy, self-reported. 4. Spinal instability 5. Unresolved deep vein thrombosis 6. Severe muscular or skeletal pain 7. Open skin ulcerations on buttocks or other body surfaces in contact with exoskeleton or harness 8. Pregnancy 9. Cognitive impairments - unable to follow 2 steps commands and communicate for pain or to stop session 10. Participant requires the assistance of more than one therapist to transfer safely. 11. Uncontrolled or severe orthostatic hypotension that limits standing tolerance; defined as sustained, symptomatic drops in systolic and diastolic blood pressure when moving from sitting to standing 12. Active heterotrophic ossification (HO), hip dysplasia or hip/knee axis abnormalities 13. Colostomy 14. History of long bone fractures secondary to osteoporosis 15. Unable to sustain current medication regimen. Participant reports change in Parkinson's Medication in the past week. 16. Any reason the therapist may deem as harmful to the participant to enroll or continue in the study
Contact & Investigator
Jacqueline Brown, DPT
PRINCIPAL INVESTIGATOR
Albert Einstein Healthcare Network
Frequently Asked Questions
Who can join the NCT06225830 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06225830 currently recruiting?
Yes, NCT06225830 is actively recruiting participants. Contact the research team at Jxb892@jefferson.edu for enrollment information.
Where is the NCT06225830 trial being conducted?
This trial is being conducted at Elkins Park, United States.
Who is sponsoring the NCT06225830 clinical trial?
NCT06225830 is sponsored by Albert Einstein Healthcare Network. The principal investigator is Jacqueline Brown, DPT at Albert Einstein Healthcare Network. The trial plans to enroll 24 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.